SCHEDULE: Wellington Management Divests Entire Akero Therapeutics Stake

Wellington Management Group and its affiliates have reported a 0.0% beneficial ownership in Akero Therapeutics, Inc. common stock, indicating a full divestment.

Summary

• Wellington Management Group LLP, Wellington Group Holdings LLP, and Wellington Investment Advisors Holdings LLP filed an Amendment No. 1 to Schedule 13G.
• The filing reports 0.0% beneficial ownership of Akero Therapeutics, Inc. common stock by all reporting persons as of December 31, 2025.
• This indicates a complete divestment of their previous holdings in Akero Therapeutics.
• The securities were certified as having been acquired and held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a moderately negative signal, as a significant institutional investor has fully divested its stake, which could imply a loss of confidence or a strategic portfolio reallocation.

Negatives

• Wellington Management Group and its affiliates have divested their entire beneficial ownership in Akero Therapeutics, Inc. common stock, reducing their stake to 0.0%.

Risks

• The complete divestment by Wellington Management Group and its affiliates may signal a lack of confidence or a change in investment strategy regarding Akero Therapeutics, Inc.

Future Outlook

This filing does not contain any forward-looking statements or guidance from Akero Therapeutics, Inc. It solely reports a change in beneficial ownership by Wellington Management Group and its affiliates.

Management Comments

• The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that institutional divestments, especially by large asset managers like Wellington Management, can sometimes precede or coincide with shifts in market sentiment or company performance within the biotechnology sector, though this filing alone does not provide the underlying reasons for the divestment.

Stakeholder Impact

• Shareholders: May interpret the complete divestment by a major institutional investor as a negative signal, potentially impacting share price and investor confidence.

Key Dates

Recommendation

The complete divestment by a major institutional investor like Wellington Management Group suggests a lack of conviction in Akero Therapeutics' future prospects. While the specific reasons are not disclosed, such a move by a sophisticated investor often precedes or reflects underlying concerns, making a 'sell' recommendation prudent for investors to re-evaluate their positions.

Keywords

Akero Therapeutics, Wellington Management, Schedule 13G, beneficial ownership, common stock, institutional ownership, divestment